CEO Bernd Montag said the company is well positioned for a “U.S. versus China situation” that could arise when Donald Trump ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

SYNDEO Medical, a Belgium-based leader in diagnostic and interventional procedural solutions, announces that its two flagship product brands, SYNDEOPack Interventional Procedure Packs™ and Xssential ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

Roots Community Health has sued 12 other firms, including GE Healthcare, CVS and Walgreens, and called for manufacturers and ...

Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation ...

The document clarifies that EtO falls within the scope of the Medical Device Regulation and the In Vitro Diagnostic ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

However, the company said it will delay a submission for its next-generation Zio cardiac monitoring system until remediation ...

Larry Jones, Johnson & Johnson Medtech’s chief information officer, will resign after more than three decades with the ...